Superworth

Guardian Pharmacy Services GRDN

Medical - Pharmaceuticals, Healthcare
$39.44
−0.38%
Market cap
$2.5B
PE
38.3×
Forward PE
n/m
not a meaningful number
Price to sales
1.7×
EV/EBIT
28.7×
Revenue, 12 months
$1.5B
+10% on a year ago
Net margin
4.5%
Free cash flow yield
n/m
not a meaningful number

Guardian Pharmacy Services trades at 38.3× trailing earnings. Revenue was $1.5B over the last twelve months, up 10% on a year earlier with a 5% net margin.

Charts

Financials

Income statement for GRDN, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$262.7M$281.1M$275.4M$300M$314.4M+20%$338.6M+21%$329.3M+20%$344.3M+15%$377.4M+20%$397.6M+17%$336.6M+2%$351.8M+2%
Cost of revenue$210.5M$226.5M$220.3M$238.7M$253.5M+20%$271.5M+20%$265M+20%$276.2M+16%$302.7M+19%$312.1M+15%$260.3M−2%$271.7M−2%
Gross profit$52.2M$54.6M$55.1M$61.3M$60.9M+17%$67.1M+23%$64.3M+17%$68.1M+11%$74.7M+23%$85.5M+27%$76.3M+19%$80M+18%
SG&A$58.5M$39.1M$47.2M$44.3M$165.5M+183%$50.3M+29%$51.3M+9%$55.6M+26%$58.4M−65%$54.7M+9%$58.6M+14%$59.4M+7%
−$6.3M$15.5M$7.9M$17M−$104.6M+1553%$16.8M+8%$13M+64%$12.6M−26%$16.4M$30.8M+84%$17.7M+36%$20.6M+64%
Interest expense$716K$739K$765K$1.1M$1M+43%$421K−43%$170K−78%$172K−84%$160K−84%$163K−61%$154K−9%$154K−11%
Pre-tax income−$7M$14.6M$7.1M$15.8M−$105.6M+1410%$16.2M+11%$13.1M+85%$12.6M−21%$16.6M$31.1M+92%$18.3M+40%$29.8M+137%
n/an/a$0$0$176K$4.4M$3.8M$3.8M$7M+3899%$9.8M+125%$4.7M+24%$7.7M+104%
Net incomen/an/a$0$0−$122M$11.9M$9.4M$9M$9.8M$20.9M+75%$13.3M+41%$21.9M+142%
n/an/an/an/a−$2.00$0.18$0.15$0.14$0.15$0.33+83%$0.21+40%$0.34+143%
n/an/an/an/a61.1M64.6M62.9M63.2M63.4M+4%63.6M−1%63.7M+1%63.8M+1%

Net income: Q1 FY24: 6 months less the 3 months printed beside them.

EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Guardian Pharmacy Services' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
GRDNGuardian Pharmacy Services$2.5B38.3×47.8×1.7×+10%4.5%
TMDXTransMedics$2.5B18.4×56.8×3.7×+26%22.7%
ADMAAdma Biologics$2.4B15.3×21.5×4.7×+8%33.0%
MDPediatrix Medical$2.4B14.0×13.4×1.2×+1%9.0%
UFPTUFP Technologies$2.3B31.9×25.6×3.6×+7%11.4%
ADUSAddus HomeCare$2.3B21.4×32.4×1.5×+16%7.1%
PBHPrestige Consumer Healthcare$2.3B13.4×15.3×2.0×−1%15.6%
NRIXNurix Therapeutics$2.8B11.0×10.8×3.9×n/m42.0%
PGNYProgyny$2.2B31.5×55.1×1.7×+6%6.0%
PRVAPrivia Health$2.9B107×158×1.2×+24%1.2%
VCELVericel$2.2B92.5×158×7.1×+23%7.9%
Peer median$2.3B19.9×29.0×2.8×+8%10.2%

More on Guardian Pharmacy Services

Each number over time

Its groups

About

Industry
Medical - Pharmaceuticals
Sector
Healthcare

Valuation data, not investment advice. Prices as of .